Allschwil, Switzerland, January 07, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, today announced an agreement with Prokaryotics Inc., a privately held US-based biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of sever ...